Abstracts Archive - Page 2027 of 2425 - ACR Meeting Abstracts

Abstract Number: 363 • 2014 ACR/ARHP Annual Meeting
Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis
Rayford R. June¹, Douglas P. Landsittel², Bruce Rabin³, S. Louis Bridges Jr.⁴, CLEAR Investigators⁵, TEAR Investigators⁵, Thomas A. Medsger Jr.⁶ and Larry W. Moreland⁶, ¹Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Pathology, Division of Clinical Immunopathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose African American (AA) patients with rheumatoid arthritis (RA) have been shown to have worse disability scores, increased disease activity scores, and reduced use of…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Anthony Marotta¹, Dirkjan van Schaardenburg², Gilles Boire³, Désirée van der Heijde⁴, Robert Landewé⁵, Maarten Boers⁶, C.F. Allaart⁷, Mairead Murphy⁸, Samina Turk⁹, Vivian P. Bykerk¹⁰, Edward Keystone¹¹, Katherine A. Siminovitch¹¹ and Walter P. Maksymowych¹², ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁹Reade, Amsterdam, Netherlands, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…
Abstract Number: 359 • 2014 ACR/ARHP Annual Meeting
14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers?
Anthony Marotta¹, Samina Turk², Mairead Murphy³, Walter P. Maksymowych⁴ and Dirkjan van Schaardenburg⁵, ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, there are auto-antibodies (AAb) to…
Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting
The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate
Gerd Burmester¹, Gurjit S. Kaeley², Jeffrey R. Curtis³, Yusuf Yazici⁴, Benoit Guerette⁵, Xin Wang⁵, Alan Friedman⁵ and Vibeke Strand⁶, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²College of Medicine, University of Florida, Jacksonville, FL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵AbbVie, Inc., North Chicago, IL, ⁶Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…
Abstract Number: 377 • 2014 ACR/ARHP Annual Meeting
Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents
Emilie Lund Egsmose¹, René Cordtz¹ and Ole Rintek Madsen², ¹Dept. of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Dept. of Rheumatoglogy/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose Fatigue (FTG) is a symptom commonly reported by patients with rheumatoid arthritis (RA). Little is known about its nature and etiology. The number of…
Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Ronald F. van Vollenhoven¹, Rebecca J. Bolce², Karen Hambardzumyan³, Saedis Saevarsdottir⁴, Kristina Forslind⁴, Ingemar Petersson⁵, Eric H. Sasso², CC Hwang⁶, Oscar Segurado² and Pierre Geborek⁷, ¹Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³ClinTRID, the Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ⁶Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Martin J. Bergman¹, Jeffrey Yourish², Jinglan Pei², Jenny Devenport², William Reiss² and Edward Keystone³, ¹Taylor Hospital, Ridley Park, PA, ²Genentech, South San Francisco, CA, ³University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…
Abstract Number: 374 • 2014 ACR/ARHP Annual Meeting
IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study
Jiayun Shen¹, Qing Shang¹, Ying Ying Leung², Shui Lian Yu¹, Chun-Kwok Wong³, Edmund Li¹, Tracy Y. Zhu¹ and Lai-Shan Tam¹, ¹Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ³Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose Clinical remission is achievable for patients with early rheumatoid arthritis (ERA). Identification of predictors for response of treatment may provide risk estimation and help…
Abstract Number: 373 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis
George A. Karpouzas¹, Joel Estis², John Todd² and Matthew Budoff³, ¹Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Singulex, Alameda, California, Alameda, CA, ³Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose Rheumatoid arthritis (RA) is associated with accelerated coronary atherogenesis, myocardial infarction, and mortality. We previously reported a higher prevalence, severity, and different composition of…
Abstract Number: 372 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain
Raashid Luqmani¹, Klara Morsley², Anne Miller³, Christopher J. Edwards⁴, M. Kassim Javaid⁵, Daniel Prieto-Alhambra⁶, Rafael Pinedo-Villanueva^7,8, Manuel Medina Peralta⁹, Sebastian Calero Munoz⁹, Nigel Arden^10,11, Francesc Fina-Aviles⁹ and Cyrus Cooper¹², ¹Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ²Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre, Oxford, United Kingdom, ³Rheumatology, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ⁴University Hospital Southampton, Southampton, United Kingdom, ⁵Rheumatology, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, ⁶NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom, ⁷NDORMS, University of Oxford, Oxford, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Institut Català de la Salut, Barcelona, Spain, ¹⁰NIHR Musculoskeletal Biomedical Research Unit University of Oxford, Oxford, United Kingdom, ¹¹University of Southampton, Southampton, United Kingdom, ¹²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom
Background/Purpose: To assess the sensitivity, specificity, and predictive values of rheumatoid factor (RF) as a test for rheumatoid arthritis (RA) in primary care, and to…
Abstract Number: 371 • 2014 ACR/ARHP Annual Meeting
The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort
Jenny Shu¹, Vivian P. Bykerk², Gilles Boire³, Carol A. Hitchon⁴, J. Carter Thorne⁵, Diane Tin⁶, Edward C. Keystone⁷, Boulos Haraoui⁸ and Janet E. Pope⁹, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Medicine, University of Toronto, Toronto, ON, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹St Joseph Health Care, London, ON, Canada
Background/Purpose: The impact of missing ACPA in early inflammatory arthritis patients was studied to determine if failure to perform ACPA testing could cause a care…
Abstract Number: 358 • 2014 ACR/ARHP Annual Meeting
Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study
Mitra Pikwer¹, Cecilia Orellana², Henrik Källberg², Andreas Pikwer³, Carl Turesson⁴, Lars Klareskog⁵, Lars Alfredsson^6,7, Saedis Saevarsdottir⁸ and Camilla Bengtsson⁹, ¹Rheumatology Unit, Mälarhospital, Institute of Environmental Medicine, Eskilstuna, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Centre of Clinical Research Sörmland, Eskilstuna, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Sweden, ⁵Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska institutet, Stockholm, Sweden, ⁶Institute of Environmental Medicine, Stockholm, Sweden, ⁷Centre of Occupational and Environmental Medicine, Stockholm, Sweden, ⁸Institute of Environmental Medicine, Karolinska Institutet,, Stockholm, Sweden, ⁹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Female sex and older age are known risk factors for rheumatoid arthritis (RA). The disease is however heterogeneous, and a common division occurs between…
Abstract Number: 357 • 2014 ACR/ARHP Annual Meeting
Development and Validation of a Diagnostic Bead-Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect “Seronegative” Rheumatoid Arthritis
Stefan Vordenbäumen¹, Angelika Lueking², Carmen Theek², Ralph Brinks¹, Rebecca Fischer-Betz¹, Jutta Richter¹, Ellen Bleck¹, Jacqueline Detert³, Gerd Burmester⁴, Peter Schulz-Knappe² and Matthias Schneider¹, ¹Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ²Protagen AG, Dortmund, Germany, ³Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁴Departement of Rhe, University Medicine, Berlin, Germany
Background/Purpose: Autoantibodies (auto-Ab) against citrullinated peptides (ACPA) and rheumatoid factor (RF) are important biomarkers in the diagnostic process of rheumatoid arthritis (RA). However, RF or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].